Skip to main content
Signal8
Launch Terminal

Oncotelic Therapeutics, Inc. (OTLC)

Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Oncotelic Therapeutics, Inc. logo

Oncotelic Therapeutics, Inc.

OTC:OTLCHealthcare
-11.62%$0.0164
Mkt Cap$7.5M
Float310.53M
O/S457.51M
Vol
$ Vol
RVOL
Inst Own-
SI0.1%
Earnings
Dilution
Oncotelic Therapeutics, Inc. logoOTC:OTLC$0.0164-11.62%
Phase Distribution
17 lead-sponsored trials·1 active·10 completed
Phase 13
Phase 1/21
Phase 28
Phase 2/33
Phase 31
Phase 41
(2 more as collaborator)
Status Overview
Not yet recruiting1
Recruiting1
Completed10
Stopped3
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Completed

    A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects

    Dexamethasone

    Covid19

    Enrollment
    120
    Start
    Sep 2020
    Primary Completion
    Feb 2021
    Completion
    Apr 2021
    NCT05004753
  • Phase 3
    Withdrawn

    Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer

    Fosbretabulin + paclitaxel + carboplatin, Placebo + paclitaxel + carboplatin

    Anaplastic Thyroid Cancer

    Enrollment
    0
    Start
    Mar 2015
    Primary Completion
    Apr 2017est.
    Completion
    Dec 2017est.
    NCT01701349
  • Phase 2/3
    Terminated

    Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

    CA4P, paclitaxel

    Anaplastic Thyroid Cancer

    Enrollment
    80
    Start
    Aug 2007
    Primary Completion
    Oct 2011
    Completion
    Nov 2011
    NCT00507429
  • Phase 2/3
    Terminated

    FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

    Fosbretabulin tromethamine, Placebo

    Platinum Resistant Ovarian Cancer

    Enrollment
    70
    Start
    Jun 2016
    Primary Completion
    Oct 2017
    Completion
    Oct 2017
    NCT02641639
  • Phase 2/3
    Recruiting

    A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

    OT-101, mFOLFIRINOX

    Pancreatic Ductal Adenocarcinoma

    Enrollment
    455
    Start
    May 2024
    Primary Completion
    Jun 2026est.
    Completion
    Jun 2027est.
    NCT06079346
  • Phase 2
    Completed

    Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors

    Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin

    Cancer, Tumor

    Enrollment
    13
    Start
    Mar 2005
    Primary Completion
    Feb 2007
    Completion
    Feb 2007
    NCT00113438
  • Phase 2
    Completed

    A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

    Fosbretabulin, Carboplatin

    Tumors

    Enrollment
    63
    Start
    Mar 2008
    Primary Completion
    Jul 2011
    Completion
    Oct 2011
    NCT00653939
  • Phase 2
    Completed

    Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

    fosbretabulin, Saline

    Polypoidal Choroidal Vasculopathy

    Enrollment
    20
    Start
    Jul 2009
    Primary Completion
    Aug 2010
    Completion
    Aug 2010
    NCT01023295
  • Phase 2
    Completed

    Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

    Combretastatin A-4 Phosphate

    Choroidal Neovascularization, Myopia, Degenerative

    Enrollment
    23
    Start
    Mar 2005
    Primary Completion
    Jan 2007
    Completion
    Jan 2007
    NCT01423149
  • Phase 2
    Completed

    A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

    fosbretabulin tromethamine

    Neuroendocrine Tumors

    Enrollment
    18
    Start
    Sep 2014
    Primary Completion
    Jun 2016
    Completion
    Aug 2016
    NCT02132468
  • Phase 2
    Completed

    Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

    fosbretabulin

    Neuroendocrine Tumors

    Enrollment
    7
    Start
    Dec 2014
    Primary Completion
    Aug 2016
    Completion
    Aug 2016
    NCT02279602
  • Phase 2
    Unknown status

    A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

    OT-101, Artemisinin

    COVID-19

    Enrollment
    18
    Start
    Apr 2021est.
    Primary Completion
    Aug 2021est.
    Completion
    Oct 2021est.
    NCT04801017
  • Phase 2
    Not yet recruiting

    OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

    OT-101

    Malignant Pleural Mesothelioma

    Enrollment
    63
    Start
    Jun 2025est.
    Primary Completion
    Dec 2028est.
    Completion
    Dec 2029est.
    NCT05425576
  • Phase 1/2
    Unknown status

    Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

    Phase 1 - OXi4503, Phase 1 - OXi4503 + cytarabine

    Acute Myelogenous Leukemia, Myelodysplastic Syndromes

    Enrollment
    105
    Start
    Oct 2015
    Primary Completion
    Oct 2019est.
    Completion
    Oct 2020est.
    NCT02576301
  • Phase 1
    Completed

    Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

    Combretastatin A4 Phosphate (CA4P), Bevacizumab (Avastin)

    Tumors

    Enrollment
    20
    Start
    Sep 2006
    Primary Completion
    Jan 2007
    Completion
    Jan 2007
    NCT00395434
  • Phase 1
    Completed

    Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden

    Combretastatin A1 Diphosphate (OXi4503)

    Neoplasm Metastasis

    Enrollment
    16
    Start
    Jul 2009
    Primary Completion
    Oct 2010
    Completion
    Oct 2010
    NCT00960557
  • Phase 1
    Completed

    Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

    OXi4503

    Solid Tumors

    Enrollment
    40
    Start
    Jul 2005
    Primary Completion
    Sep 2010
    Completion
    -
    NCT00977210
Search ClinicalTrials.gov for “Oncotelic Therapeutics”